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We here report the preparation of a new 2,6,8-trisubstituted bicyclic tripeptidomimetic scaffold through TFA-
mediated cyclization of a linear precursor containing three side chains. The introduction of a 
triphenylmethyl-protected thiol into carboxylic acid containing building blocks through sulfa Michael 
additions onto a,b-unsaturated hexafluoroisopropyl esters is described. The stereoselectivity of the bicycle 
formation was found to be somewhat lower than that previously reported for analogous 3,6,8-trisubstituted 
scaffolds. Moreover, the configuration of the linear precursor directs the stereochemical outcome of the 
cyclization differently when the R1 side chain is positioned on C2 in the bicycles (present work) instead of 
C3 (previous work). Tripeptidomimetic compounds based on the new scaffold were synthesized and 
evaluated for antagonistic potency toward CXCR4, and one compound (45a) displayed similar activity to 





























Endogenous and exogenous peptides display a multitude of important activities related to human disease 
states, and both the processing of peptide substrates and the binding of signalling peptides have been targeted 
for therapeutic purposes. Thus, proteolytic enzymes (proteases) as well as peptide-binding (peptidergic) 
receptors are targets for drugs. Compounds that interfere with either processing or signalling of peptides are 
commonly referred to as peptidomimetics, and have been classified as either peptide backbone mimetics 
(type I), functional mimetics (type II) or topographical mimetics (type III).1 Peptidomimetic structures have 
found widespread use as drugs, and in a drug discovery perspective, tripeptidomimetics have been identified 
as particularly interesting.2 
We have previously reported the synthesis of a novel type of tripeptidomimetics based on a 3,6,8-
trisubstituted 4,7-dioxo-1-thia-5,8-diaza-bicyclo[4.4.0]decane scaffold (Figure 1A).3 These compounds were 
Arg1-Arg2-2-Nal3 (2-napthylalanine, 2-Nal) mimetics and were designed as antagonists for the CXC 
chemokine receptor 4 (CXCR4), which is a 7TM receptor involved in entry of T-tropic HIV strains into 
CD4+ T-cells,4,5 and also has a pathological role in cancer and rheumatoid arthritis.6 The prototype 
compounds 1a and 1b (Figure 1A) were shown to have EC50 values of 64 µM and 80 µM, respectively, in a 
cell-based assay for wild-type CXCR4.3 We recently reported an array of close analogues aimed at 
investigating the influence of side chain length (m = 2-4, n = 3-4, o = 1-2) on antagonistic potency, where 
2a,b (Figure 1A; isolated as a mixture of diastereoisomers) showed an EC50 of 61 µM.7 
 
 
Figure 1. A) Bicyclic scaffold A and tripeptidomimetic CXCR4 antagonists based on scaffold A3,7; B) Bicyclic scaffold B. 
 
Our tripeptidomimetic compounds are inspired by a series of highly potent cyclopentapeptide CXCR4 
antagonists originally reported by Fujii et al.8 The most potent cyclopentapeptides were based on the amino 
acid sequence L/D-Arg1-Arg2-2-Nal3-Gly4-D-Tyr5, where the Arg1-position was shown to be relatively 























































that re-positioning of the Arg1 side chain to give N-alkylated D-Ala1 cyclopentapeptide analogues resulted in 
high antagonistic potency.9 For our approach, we envisioned that the 2,6,8-trisubstituted scaffold B (Figure 
1B) would be suited to present the side chains of the Arg1-Arg2-Nal3 tripeptide fragment in a similar manner 
as for the cyclopentapeptides. In this scaffold, the C2-C3 bond would correspond to the Ca-Cb vector of the 
Arg1 side chain, resulting in an additional conformational constraint. Our synthetic endeavours toward this 
novel scaffold are reported herein. 
 
2. Results and Discussion 
 
2.1. Synthesis 
In our previous syntheses of tripeptidomimetic compounds, the building blocks bearing the R1 side chain 
were prepared without any attempts at controlling the configuration of the chiral centre.7,3 Consequently, two 
diastereoisomers (a and b, Figure 1A) of the scaffold A bicycles were formed in the cyclization. The sulfa 
Michael-type addition of the deprotected thiol onto the acyliminium ion intermediate was highly 
stereoselective, as initially investigated by Grimes et al.,10 and resulted in two diastereomeric bicycles where 
H6 and H9a always displayed a cis relationship.7,3 
 
In our earlier syntheses of building blocks for scaffold A with different chain length for the R1 side chain, the 
sulfur atom was introduced through a Michael addition between triphenylmethanethiol and N-Boc protected 
a-methylenyl lactams of varying ring size.3,7 Subsequent hydrolysis of the N-Boc protected lactams11 gave 
the required N-Boc protected w-amino carboxylic acids. For scaffold B, we envisioned that a Michael 
acceptor with an endocyclic double bond would give access to an array of building blocks with varying 
methylene spacer length for the R1 side chain. Toward this end, we started out by converting N-Boc lactam 3 
into α,β-unsaturated lactam 4 through reaction of the corresponding enolate with N-tert-
butylbenzenesulfinimidoyl chloride at −78 °C (Scheme 1).12 The α,β-unsaturated lactam 4 was difficult to 
separate from the starting material and was isolated as a ~10:1 mixture with 3; however, in the subsequent 
addition step, the desired Michael adduct 5 could be isolated in pure form. Finally, hydrolysis of 5 gave 
carboxylic acid 6 in high yield. 
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Scheme 1. Reagents and conditions: a) i) LDA, THF, -78 °C ii) PhS(Cl)=N-t-Bu, THF, -78 °C (90%, 4/3 ~10:1); b) Ph3CSH, 
Et3N, CH2Cl2 (68%); c) 1 M aq. LiOH, THF (82%). 
 
For elongation of the R1 side chain, N-Boc protected lactam 7 (Scheme 2) was treated with LiHMDS in dry 
THF to form the corresponding enolate, which was reacted with phenylselenyl chloride to give 
phenylselenide 8.13 Oxidation with hydrogen peroxide to the selenoxide gave in turn the α,β-unsaturated 
lactam 9. However, this material proved to be difficult to purify, and the crude product was therefore used 
directly in the Michael addition.14 Triphenylmethanethiol was used as the Michael donor in the presence of 
triethylamine as base and dry CH2Cl2 as solvent, but this reaction was unsuccessful. By changing the solvent 
to anhydrous DMF, the Michael product 10 was obtained in 66% yield over two steps. Finally, hydrolysis 
gave carboxylic acid 11. 
 
Scheme 2. Reagents and conditions: a) i) LiHMDS, THF, -78 °C, ii) PhSeCl, THF, -78 °C (86%); b) H2O2, THF, 0 °C; c) Ph3CSH, 
Et3N, DMF (66% over two steps); d) 1 M aq. LiOH, THF (71%). 
 
While the Michael addition worked well both for the six- and seven-membered lactams, reaction with 12 
(Scheme 3) did however not proceed according to plan (data not shown). Although the m/z for the Michael 
product 13 was observed for the crude product, all attempts at isolating the product by flash column 
chromatography proved to be unsuccessful. One reason for the poor outcome might be lower ring-strain for 
the eight-membered α,β-unsaturated lactam 12 leading to lower reactivity than the six- and seven-membered 
analogues. Since we were planning to prepare bicyclic analogues with an R1 side chain containing five 
methylene groups, which would require Michael addition onto an a,b-unsaturated 9-membered lactam, we 







































Scheme 3. Reagents and conditions: a) Ph3CSH, Et3N, DMF. 
 
In order to access derivatives with a longer methylene chain for the R1 group, we decided to employ α,β-
unsaturated methyl esters 19 and 20 as Michael acceptors (Scheme 4), which were prepared starting from 
amino alcohols 14 and 15 through N-protection15 followed by oxidation to aldehydes and then Wittig reaction 
with methyl (triphenylphosphoranylidene)acetate (Scheme 4). 
 
Scheme 4. Reagents and conditions: a) Boc2O, 1,4-dioxane, 0 °C to rt; b) TBDMSCl, imidazole, CH2Cl2, 0 °C; c) i) n-BuLi, THF, 
0 °C, ii) Boc2O, THF, 0 °C to rt; d) TBAF, THF (16: 52% over 4 steps); e) TEMPO, n-Bu4NCl, NCS, CH2Cl2 (18: 37% over 2 
steps); f) Dess-Martin periodinane, CH2Cl2, 0 °C; g) MeOC(O)CHP(Ph)3, THF, 60 °C (19: 81% over 2 steps; 20: 57%). 
 
Michael addition with triphenylmethanethiol onto α,β-unsaturated methyl esters (such as 19 and 20) proved 
to be very unreliable. Complete conversion of the starting material could never be achieved, albeit a variety 
of different conditions were tested.16 In addition, triphenylmethanethiol decomposed during the reactions to 
give products with similar Rf values as the desired Michael addition products, which hampered purification 
by flash column chromatography. As the methyl esters 19 and 20 proved to be too unreactive, we decided to 
increase the electrophilicity by conversion into hexafluoroisopropyl esters 21 and 22 (Scheme 5) through 
DCC mediated esterification.17 The Michael addition now gave protected thiols, which were hydrolysed to 
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Scheme 5. Reagents and conditions: a) 1) 1 M aq. LiOH, THF; b) 1,1,1,3,3,3-hexafluoropropan-2-ol, DMAP, DIC, CH2Cl2 (21: 
62%; 22: 61%, both over 2 steps); c) Ph3CSH, Et3N, CH2Cl2 (23: 52%; 24: 91%); d) 1 M aq. LiOH, THF (25: 33%; 26: 56%). 
 
In order to elongate the R3-side chain compared to our previously reported antagonists based on scaffold A,3 
secondary amine 29 was prepared from N-Boc protected allylamine 28 through hydroboration followed by 
Suzuki-Miyaura coupling and then Boc-deprotection followed by alkylation (Scheme 6).18 
 
Scheme 6. Reagents and conditions: a) 9-BBN, THF; b) 2-Bromonapthalene, Pd(dppf)2Cl2•CH2Cl2, 1 M NaOH; c) NaOH, H2O2, 
H2O, THF, 0 °C (70% over 3 steps); d) TFA, CH2Cl2, 0 °C; e) BrCH2CH(OMe)2, K2CO3, DMF, 80 °C (31% over 2 steps); f) 
Fmoc-Arg(Pbf)-OH, HATU, DIPEA, CH2Cl2 (79%). 
 
Next, the R1 side chain bearing carboxylic acids were coupled with the Fmoc-deprotected R2-R3 fragments 
30 and 313 (Scheme 7). The resulting linear precursors 32-37 (inseparable mixture of diastereoisomers) were 
submitted to TFA-mediated deprotection and cyclization to give bicyclic compounds 38-43, which were 
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Scheme 7. Reagents and conditions: a) Et2N, CH2Cl2; b) 6, 11, 25 or 26, HATU, DIPEA, CH2Cl2 (20-77% over 2 steps); c) 
TFA/H2O/thioanisole (90:5:5); d) 1H-Pyrazole-1-carboxamidine hydrochloride, DIPEA, DMF (8-42% over 2 steps). 
 
Interestingly, the outcome of the cyclisation of linear precursors for scaffold B was different than for scaffold 
A (Figure 1A).10,3,7 For scaffold A, TFA-treatment of the mixture of diastereoisomeric linear precursors led 
to the formation of two cyclization products, however the cyclization of 32-37 gave two major and either one 
or two minor peaks as evident by HPLC analysis (see Figure S1). From this point on, the two major 
guanidinylation products are denoted a and b, and the minor compounds are denoted c and d. MS analysis 
revealed that all these peaks had the expected m/z of the cyclized products. 
 
The crude guanidinylation products were purified by semi-preparative RP-HPLC, however separation proved 
to be difficult due to small differences in retention time between the isomers. Pure diastereoisomers could not 
be obtained for every analogue and when separation was impossible, mixtures of two isomers were collected 
and analysed by NMR spectroscopy and mass spectrometry. 
 
2.2. NMR Studies on Scaffold B Analogues 
In order to assign the configuration of the newly formed chiral centres at C2 and C9a (Figure 1B) for the 
different cyclization products, the 2D 1H ROESY experiment was used. As was the case for scaffold A, the 
known configuration of C6 was used as a starting point. The configuration of C9a for 45a and 45b (Figure 2) 
could be determined by the presence of strong cross-peaks between H9a and Hβ/Hγ of the R2 side chain in 
the ROESY spectrum of 45a, while these were absent in the spectrum of 45b. Further, the ROESY spectra of 
both the a and b fractions showed no cross-peaks between H2 and H9a, indicating that these are trans to each 
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observations suggest a (2S,6S,9aS) configuration for 45a  and a (2R,6S,9aR) configuration for 45b as 
depicted in Figure 2.  
 
Figure 2. Suggested configuration of major isomers a and b. 
 
These assignments were further supported by the combination of strong cross-peaks for H9a/Hb3 (see Figure 
2), a strong cross-peak for H2/Ha3, a weaker cross-peak for H2/Hb3 and the absence of a H9a/Ha3 cross-peak 
in the ROESY spectrum for 45a. This suggests that H9a and Hb3 are oriented cis, while H2 is oriented trans 
to Hb3 and cis to Ha3 for 45a. For 45b, the H9a/H3 and H2/H3 correlations were reversed. The NMR data for 
the a and b diastereoisomers of 44 and 46-49 were consistent with those of 45a and 45b. 
 
Isomers c and d could never be isolated in pure form, only as a mixture with varying amounts of isomer b. 
For 48 and 49, the NMR signals for the two minor products could be partially assigned based on 2D NMR 
spectra of the mixtures with the b isomer (see Table S1 for a comparison of 1H chemical shifts for H2, H6 
and H9a). The 2D 1H ROESY spectra did however not provide a clear-cut answer with regards to the 
configurational assignment of C2 and C9a, as the spectra were quite crowded and signals overlap in several 
cases. Based on the 2D NMR and HRMS data, the four products are clearly all bicyclic, and all of them have 
different chemical shifts for the methine protons of the bicycles. Unfortunately, our present NMR data does 
not allow for an unequivocal assignment of the configuration of the chiral carbon atoms for isomers c and d. 
Interestingly, Grimes et al.10 noted that in the absence of an R1 substituent, cyclization of linear precursors 
gave a 90:10 mixture of diastereoisomers, which is comparable to the ratio between major and minor 
cyclization products in the present work. 
 
2.3. Biological Activity for Scaffold B Analogues 
The antagonistic potency on human CXCR4 for compounds 44-49 was tested in a functional assay and 45a 
showed activity with an EC50 value of 61 µM, while its diastereoisomer 45b was inactive (Table 6). As none 
of the other synthesised scaffold B analogues were active, this indicates that a three-carbon atom spacer in 
the R1 side chain is the optimum. On the other hand, it seems detrimental to increase the R3 side chain spacer 










































2 3  
> −4 >100 >95% 
44b > −4 >100 >95% 
45a 
3 3  
−4.21 ± 0.01 61 >95% 
45b > −4 >100 >95% 
46a 
4 3  
> −4 >100 >95% 
46b,c,d > −4 >100 8:2 b/c+d 
47a 
5 3  
> −4 >100 >95% 
47b > −4 >100 >95% 
48a 
3 3  
> −4 >100 >95% 
48b,c > −4 >100 8:2 b/c 
48b,d > −4 >100 2:8 b/d 
49a 
5 3  
> −4 >100 >95% 
49b,c > −4 >100 7:3 b/c 
49b,d > −4 >100 1:9 b/d 
 
3. Conclusions 
A new 2,6,8-trisubstituted bicyclic scaffold has been prepared for the first time, and through 2D NMR studies 
we have determined the configuration for the major isomer formed. The configuration of the linear precursor 
directed the stereochemical outcome of the cyclization differently whether the R1 side chain is positioned on 
C2 (this work) compared to C3 (previous work) in the bicycles. All reports on cyclization to obtain 
derivatives of 3,6,8-trisubstituted 4,7-dioxo-1-thia-5,8-diaza-bicyclo[4.4.0]decane gave isomers with H3 and 
H9a in a cis relationship, whereas we in this work found that for derivatives of 2,6,8-trisubstituted 4,7-dioxo-






















diastereoselectivity in cyclizations to give 3,6,8-trisubstituted bicycles has been reported,10,3,7 however for the 
2,6,8-substitution pattern the diastereoselectivity was lower, with the major and minor isomers formed in an 
approximately 9:1 ratio. With respect to antagonistic potency toward CXCR4, we found that analogue 45a 
displayed comparable activity to our original hit compounds based on the 3,6,8-trisubstituted scaffold and 
that a three carbon spacer seems to be optimal for the R1 side chain. 
 
4. Experimental 
4.1. Chemistry - All starting materials, reagents and solvents were purchased from Sigma-Aldrich and used 
as delivered unless stated otherwise. Compounds 4,12 1619 and 313 were prepared according to literature 
procedures and their analytical data were found to be in accordance with those reported. Anhydrous THF was 
obtained from an anhydrous solvent delivery system (SDS-800 from mBraun) at the Department of 
Chemistry, University of Bergen. CH2Cl2 was dried over molecular sieves. For analysis by thin layer 
chromatography (TLC), aluminium sheets coated with Merck KGaA silica gel (60 F254) were used. The TLC 
plates were visualized using either ultraviolet light or by immersion in a solution of 2% ninhydrin in ethanol 
supplemented with 10 drops of concentrated sulfuric acid per 100 mL solution, followed by heating. 
Purification by flash column chromatography was performed on Merck KGaA Kieselgel (230 – 400 mesh). 
All final compounds were purified by semi-preparative RP-HPLC eluting with mixtures of acetonitrile and 
H2O (both containing 0.1% TFA). Fractions of equal purity were pooled and lyophilized. All tested 
compounds were analysed by RP-HPLC and the purity is specified for each compound below. NMR spectra 
were obtained on a Bruker Biospin DPX400, a Bruker Biospin AV500, a Bruker Biospin AV600 or a Bruker 
Biospin 850SB. High resolution mass spectra were obtained on a JEOL AccuTOFTM JMS T100LC which 
was operated in ESI mode. 
 
4.1.1. tert-Butyl 2-oxo-4-(tritylthio)piperidine-1-carboxylate (5) 
To a stirred mixture of N-Boc-protected a,b-unsaturated lactam 4 (339 mg, 1.55 mmol) and 
triphenylmethanethiol (639 mg, 2.33 mmol) in dry CH2Cl2 (9.0 mL) was added triethylamine (325 µL, 2.33 
mmol). The reaction mixture was stirred at room temperature for 29 h, diluted with CH2Cl2 (25 mL) and 
washed with saturated NaCl (20 mL). The solvent was removed under reduced pressure to give the crude 
product (1.27 g). Purification by automated column chromatography on silica gel (hexanes/EtOAc, 8:2) gave 
the title compound (503 mg, 68%). Rf (hexanes/EtOAc, 8:2) = 0.21; 1H NMR (400 MHz, CDCl3): δ = 7.50 – 
7.43 (m, 6H), 7.33 – 7.27 (m, 6H), 7.25 – 7.19 (m, 3H), 3.60 (dt, J = 12.9, 5.0 Hz, 1H), 3.17 – 3.08 (m, 1H), 
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2.60 – 2.50 (m, 2H), 2.44 – 2.34 (m, 1H), 1.47 (s, 9H), 1.46 – 1.38 (m, 2H); 13C NMR (100.6 MHz, CDCl3): 
δ = 169.1, 152.4, 144.6, 129.5, 128.2, 127.0, 83.2, 68.0, 44.9, 42.1, 37.8, 30.6, 28.0; HRMS (ESI): m/z 
[M+Na]+ calcd for C29H31NO3SNa+: 496.1917; found: 496.1924. 
 
4.1.2. 5-((tert-Butoxycarbonyl)amino)-3-(tritylthio)pentanoic acid (6) 
To a stirred solution of tert-butyl 2-oxo-4-(tritylthio)piperidine-1-carboxylate (approximately 500 mg, 1.05 
mmol) in THF (5.0 mL) was added LiOH (1 M, 2.0 mL, 2.0 mmol). The reaction mixture was stirred at room 
temperature and monitored by TLC. After 1 h the starting material was consumed completely and the solvent 
was removed under reduced pressure. The aqueous residue was acidified to pH ~4 with 10% citric acid and 
extracted with CH2Cl2 (20 mL, then 3 x 5 mL). The combined organic layer was washed with saturated NaCl 
(40 mL), dried over anhydrous MgSO4, filtered and concentrated to give the crude product (477 mg). 
Purification by flash column chromatography on silica gel (CH2Cl2/MeOH, 95:5) gave the title compound as 
a colorless oil (424 mg, 82%). Rf (CH2Cl2/MeOH, 95:5) = 0.20; 1H NMR (500 MHz, CDCl3): δ = 7.55 – 7.51 
(m, 6H), 7.29 (t, J = 7.7 Hz, 6H), 7.22 – 7.18 (m, 3H), 4.25 (bs, 1H), 3.16 – 2.96 (m, 2H), 2.60 (s, 1H), 2.34 – 
2.11 (m, 2H), 1.72 – 1.62 (m, 1H), 1.56 – 1.47 (m, 1H), 1.41 (s, 9H); 13C NMR (150.9 MHz, CDCl3): δ = 
176.5, 156.0, 144.8, 129.6, 128.1, 126.9, 79.3, 67.8, 39.7, 38.4, 37.8, 35.0, 28.5; HRMS (ESI): m/z [M+Na]+ 
calcd for C29H33NO4SNa+: 514.2023; found: 514.2030. 
 
4.1.3. tert-Butyl 2-oxo-3-(phenylselanyl)azepane-1-carboxylate (8) 
Lithium bis(trimethylsilyl)amide (1.0 M in THF, 1.80 mL, 1.80 mmol) was added drop-wise to a stirred 
solution of N-Boc 6-aminohexanoic acid lactam (0.30 mL, 1.46 mmol) in dry THF (3 mL) at -78 °C. The 
solution was stirred for 1 h before phenylselenyl chloride (0.36 g, 1.90 mmol) in dry THF (3 mL) was added 
drop-wise. After 2 h of stirring at -78 °C the reaction mixture was allowed to warm to room temperature 
before HCl (1.0 M, 10 mL) was added to quench the reaction. The reaction mixture was extracted with 
EtOAc (3 x 10 mL) and the combined organic layers were washed with NaHCO3 (10%, 30 mL) and saturated 
NaCl (30 mL) and dried over anhydrous MgSO4. The solvent was removed under reduced pressure to give 
the crude product (624 mg). Purification by flash column chromatography on silica gel (hexanes/EtOAc, 9:1) 
gave the title compound as a white solid (462 mg, 86%). Rf (hexanes/EtOAc, 9:1) = 0.16; 1H NMR (400 
MHz, CDCl3): δ = 7.62 – 7.58 (m, 2H), 7.31 – 7.26 (m, 3H), 4.29 (dd, J = 9.4, 2.5 Hz, 1H), 4.10 – 4.02 (m, 
1H), 3.75 – 3.67 (m, 1H), 2.21 – 2.11 (m, 1H), 2.09 – 1.97 (m, 1H), 1.89 – 1.79 (m, 1H), 1.76 – 1.65 (m, 2H), 
1.64 – 1.55 (m, 1H), 1.52 (s, 9H); 13C NMR (100.6 MHz, CDCl3): δ = 173.7, 153.2, 134.6, 129.6, 129.3, 
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128.1, 83.3, 51.1, 45.7, 31.6, 28.4, 28.3, 28.1; HRMS (ESI): m/z [M+Na]+ calcd for C17H23NO3SeNa+: 
392.0735; found: 392.0743. 
 
4.1.4. tert-Butyl 2-oxo-4-(tritylthio)azepane-1-carboxylate (10) 
A stirred solution of 8 (77 mg, 0.21 mmol) in THF (0.5 mL) was cooled to 0 °C and H2O2 (30%, 50 µL, 0.44 
mmol) was added drop-wise. The reaction mixture was stirred at 0 °C for 17 minutes and then warmed up to 
room temperature over 20 minutes. The reaction mixture was separated between CH2Cl2 (5 mL) and 
saturated NaHCO3 (5 mL). The aqueous layer was extracted with CH2Cl2 (5 mL) and the combined organic 
layers were washed with saturated NaCl and dried over MgSO4. The solvent was removed under reduced 
pressure to give the crude N-Boc (Z) 6-aminohex-2-enoic acid lactam (9) as yellow oil (58 mg). The crude 
product (58 mg) and triphenylmethanethiol (156 mg, 0.56 mmol) were dissolved in anhydrous DMF (3 mL). 
Triethylamine (80 µl, 0.58 mmol) was added and the reaction mixture was stirred for 18 h. The solvent was 
removed under reduced pressure to give the crude product (290 mg). Purification by flash column 
chromatography on silica gel (hexanes/EtOAc, 4:1) gave the title compound as white foam (68 mg, 66% over 
two steps). Rf (hexanes/EtOAc, 4:1) = 0.19; 1H NMR (400 MHz, CDCl3): δ = 7.51 – 7.46 (m. 6H), 7.31 – 
7.25 (m, 6H), 7.22 – 7.17 (m, 3H), 3.68 – 3.54 (m, 2H), 2.72 – 2.54 (m, 3H), 1.88 – 1.76 (m, 1H), 1.48 (s, 
9H), 1.46 – 1.30 (m, 3H); 13C NMR (150.9 MHz, CDCl3): δ = 172.3, 152.6, 144.8, 129.7, 128.1, 126.9, 82.9, 
68.3, 46.3, 45.3, 39.9, 35.7, 28.2, 26.2; HRMS (ESI): m/z [M+Na]+ calcd for C30H33NO3SNa+: 510.2073; 
found: 510.2078; m/z [2M+Na]+ calcd for C60H66N2O6S2Na+: 997.4255; found: 997.4283.  
 
4.1.5. 6-(tert-Butoxycarbonylamino)-3-(tritylthio)hexanoic acid (11) 
To a stirred solution of 10 (118 mg, 0.24 mmol) in THF (1 mL) was added LiOH (1.0 M, 0.73 mL, 0.73 
mmol). The reaction was monitored by TLC and all starting material was consumed after 1 h. The solvent 
was removed under reduced pressure and the aqueous residue was acidified to pH 4 with 10% citric acid 
followed by extraction with CH2Cl2 (20 mL, then 3 x 5 mL). The organic layers were combined, washed with 
saturated NaCl (25 mL), dried over anhydrous MgSO4 and concentrated to give the crude product (117 mg). 
Purification by flash column chromatography on silica gel (CH2Cl2/MeOH, 95:5) gave the title compound as 
a colorless oil (87 mg, 71%). Rf (CH2Cl2/MeOH, 95:5) = 0.23; 1H NMR (600 MHz, CDCl3): δ = 7.55 – 7.52 
(m, 6H), 7.31 – 7.27 (m, 6H), 7.23 – 7.19 (m, 3H), 4.57 (bs, 1H), 3.00 – 2.86 (m, 2H), 2.70 – 2.63 (m, 1H), 
2.24 (dd, J = 16.1, 9.4 Hz, 1H), 2.04 (d, J = 15.9 Hz, 1H), 1.44 (s, 9 H), 1.41 – 1.31 (m, 4H); 13C NMR 
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(125.8 MHz, CDCl3): δ = 175.5, 156.0, 144.9, 129.6, 128.1, 126.8, 79.2, 67.6, 40.6, 40.3, 39.6, 31.8, 28.5, 
26.4; HRMS (ESI): m/z [M+Na]+ calcd for C30H35NO4SNa+: 528.2179; found: 528.2187. 
 
4.1.6. tert-Butyl (6-oxohexyl)carbamate (18) 
To a stirred solution of crude 17 (1.92 g) in dry CH2Cl2 (10 mL) at 0 °C was added Dess-Martin periodinane 
(3.74 g, 8.81 mmol). The reaction mixture was stirred at room temperature for 25 h. Slow addition of a 
mixture of saturated NaHCO3/saturated Na2S2O3 (1:1, 10 mL) and stirred for another 30 minutes. The two 
layers were separated, and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic 
layers were washed with H2O (2 x 20 mL) and saturated NaCl (20 mL), dried over anhydrous MgSO4, 
filtered and concentrated to give the crude product as light yellow oil (2.03 g). Purification by flash column 
chromatography on silica gel (hexanes/EtOAc, 6:4) gave the title compound as colorless liquid (661 mg, 37% 
over 2 steps). Rf (hexanes/EtOAc, 6:4) = 0.38; 1H NMR (500 MHz, CDCl3): δ = 9.76 (t, J = 1.8 Hz, 1H), 4.58 
(bs, 1H), 3.16 – 3.06 (m, 2H), 2.43 (td, J = 7.3, 1.6 Hz, 2H), 1.65 (p, J = 7.5 Hz, 2H), 1.54 – 1.47 (m, 2H), 
1.44 (s, 9H), 1.39 – 1.32 (m, 2H); 13C NMR (125.8 MHz, CDCl3): δ = 202.6, 156.1, 79.2, 43.8, 40.4, 30.0, 
28.5, 26.4, 21.8; HRMS (ESI): m/z [M + Na]+ calcd for C11H21NO3Na+: 238.1414; found: 238.1418; m/z [2M 
+ Na]+ calcd for C22H42N2O6Na+: 453.2935; found: 453.2930. 
 
4.1.7. Methyl (E)-7-((di-tertbutoxycarbonyl)amino)hept-2-enoate (19) 
To a stirred solution of 16 (195 mg, 0.64 mmol) in CH2Cl2 (5 mL) at 0 °C was added Dess-Martin 
periodinane (319 mg, 0.75 mmol). The reaction mixture was stirred at 0 °C for 2 h. Saturated 
NaHCO3/saturated Na2S2O3 (1:1, 10 mL) was added drop wise to the reaction mixture and stirring continued 
for 30 minutes. The two layers were separated and the aqueous layer was extracted with diethyl ether (4 x 10 
mL). The organic layers were combined, washed with H2O (3 x 20 mL) and saturated NaCl (20 mL), dried 
over anhydrous MgSO4 and concentrated to give the crude product (193 mg), which was used in the 
subsequent step without purification. To a stirred solution of the crude aldehyde (193 mg) made in the 
previous step in dry THF (5 mL) was added methyl (triphenylphosphoranylidene)acetate (454 mg, 1.36 
mmol). The reaction mixture was stirred at 60 °C for 24 h. The solvent was removed under reduced pressure 
to give the crude product as an orange solid (620 mg). Purification by flash column chromatography on silica 
gel (hexanes/EtOAc, 8:2) gave the title compound (187 mg, 81%). Rf (hexanes/EtOAc, 8:2) = 0.34; 1H NMR 
(500 MHz, CDCl3): δ = 6.95 (dt, J = 15.6, 7.0 Hz, 1H), 5.82 (dt, J = 15.6, 1.5 Hz, 1H), 3.72 (s, 3H), 3.57 (t, 
7.3 Hz, 2H), 2.25 – 2.20 (m, 2H), 1.64 – 1.56 (m, 2H), 1.50 (s, 18H), 1.48 – 1.42 (m, 2H); 13C NMR (125.8 
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MHz, CDCl3): δ = 167.2, 152.9, 149.2, 121.3, 82.3, 51.6, 46.2, 32.0, 28.7, 28.2, 25.4; HRMS (ESI): m/z 
[M+Na]+ calcd for C18H31NO6Na+: 380.2044; found: 380.2047. 
 
4.1.8. Methyl (E)-8-((tert-butoxycarbonyl)amino)oct-2-enoate (20) 
Boc-protected aldehyde 18 (640 mg, 2.97 mmol) was dissolved in dry THF (15 mL) and 
methyl(triphenylphosphoranylidene)acetate (1.40 g, 4.17 mmol) was added. The mixture was stirred at 60 °C 
for 21 h under argon atmosphere. The solvent was removed under reduced pressure to give the crude product 
as a yellow solid (1.95 g). Purification by flash chromatography on silica gel (hexanes/EtOAc 7:3) gave the 
title compound as a colorless liquid (456 mg, 57%). Rf (hexanes/EtOAc, 7:3) = 0.37; 1H NMR (500 MHz, 
CDCl3): δ = 6.95 (dt, J = 15.6, 7.0 Hz, 1H), 5.82 (dt, J = 15.7, 1.5 Hz, 1H), 4.59 (bs, 1H), 3.72 (s, 3H), 3.17 – 
3.01 (m, 2H), 2.21 (qd, J = 7.2, 1.6 Hz, 2H), 1.52 – 1.46 (m, 4H), 1.44 (s, 9H), 1.38 – 1.30 (m, 2H); 13C 
NMR (125.8 MHz, CDCl3): δ = 167.2, 156.1, 149.4, 121.2, 79.1, 51.5, 40.5, 32.1, 30.0, 28.5, 27.8, 26.4; 
HRMS (ESI): m/z [M+Na]+ calcd for C14H25NO4Na+: 294.1676; found: 294.1683. 
 
4.1.9. 1,1,1,3,3,3-hexafluoropropan-2-yl (E)-7-((di-tert-butoxycarbonyl)amino)hept-2-enoate (21) 
LiOH (1 M, 1.6 mL, 1.6 mmol) was added to a stirred solution of unsaturated methyl ester 19 (187 mg, 0.52 
mmol) in THF (2 mL). The reaction mixture was stirred for room temperature for 11.5 h. The solvent was 
removed under reduced pressure and the pH of the aqueous residue was acidified to pH ~ 4 with 10% citric 
acid. The mixture was extracted with CH2Cl2 (4 x 10 mL) and the combined organic layer was washed with 
saturated NaCl (25 mL), dried over anhydrous MgSO4 and concentrated to give the crude product (170 mg). 
Analysis by ESI-MS showed incomplete conversion of starting material, therefore the crude product (170 
mg) was dissolved in THF (2 mL) and treated with LiOH (1 M, 6 mL, 6 mmol). The reaction mixture was 
stirred at room temperature for 20 h. The solvent was removed under reduced pressure and the pH of the 
aqueous residue was acidified to pH ~ 4 with 10% citric acid. The mixture was extracted with CH2Cl2 (4 x 10 
mL), the combined organic layer was washed with saturated NaCl (25 mL), dried over anhydrous MgSO4 
and concentrated to give the crude product (151 mg), which was used in the next step without purification. 
To a stirred solution of crude carboxylic acid (151 mg) in dry CH2Cl2 (2 mL) was added DMAP (24 mg, 0.19 
mmol), DIC (80 µL, 0.52 mmol) and 1,1,1,3,3,3-hexafluoropropan-2-ol (60 µL, 0.57 mmol). The reaction 
mixture was stirred at room temperature for 21.5 h and then diluted with CH2Cl2 (15 mL), washed with 
saturated NH4Cl (10 mL) and saturated NaCl (10 mL). The organic layer was dried over anhydrous MgSO4 
and concentrated to give the crude product (408 mg). Purification by flash column chromatography on silica 
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gel (hexanes/EtOAc, 9:1) gave the title compound (160 mg, 62% over 2 steps). Rf  (hexanes/EtOAc, 9:1) = 
0.28; 1H NMR (600 MHz, CDCl3): δ = 7.20 (dt, J = 15.6, 6.9 Hz, 1H), 5.94 (dt, J = 15.7, 1.6 Hz, 1H), 5.82 
(sep, J = 6.1 Hz, 1H), 3.58 (t, J = 7.3 Hz, 2H), 2.34 – 2.29 (m, 2H), 1.64 – 1.58 (m, 2H), 1.54 – 1.45 (m, 
20H); 13C NMR (125.8 MHz, CDCl3): δ = 162.9, 154.7, 152.8, 120.6 (q, 1JCF = 283.1 Hz), 118.3, 82.4, 66.4 
(sep, 2JCF = 34.5 Hz), 46.0, 32.3, 28.5, 28.2, 25.0; HRMS (ESI): m/z [M+Na]+ calcd for C20H29F6NO6Na+: 
516.1791; found: 516.1800. 
 
4.1.10. 1,1,1,3,3,3-Hexafluoropropan-2-yl (E)-8-((tert-butoxycarbonyl)amino)-oct-2-enoate (22) 
Methyl ester 20 (385 mg, 1.42 mmol) was dissolved in THF (10 mL) and LiOH (1 M, 4.50 mL, 4.50 mmol) 
was added. The mixture was stirred at room temperature for 16.5 h. The solvent was removed under reduced 
pressure upon completion and the aqueous residue was acidified to pH 4 with 10% citric acid and extracted 
with CH2Cl2 (3 x 40 mL). The combined organic layers were washed with saturated NaCl (3 x 50 mL) and 
dried over anhydrous MgSO4, filtered and concentrated to give the crude product as an orange solid (334 
mg), which was used in the next step without purification.  
To a stirred solution of crude carboxylic acid (324 mg, 1.26 mmol) in dry CH2Cl2 (3 mL) was added 
1,1,1,3,3,3-hexafluoro-2-propanol (0.16 mL, 1.52 mmol), DMAP (63 mg, 0.52 mmol) and DIC (0.25 mL, 
1.61 mmol). The reaction mixture was stirred for 20 h and then diluted with CH2Cl2 (25 mL), washed with 
saturated NH4Cl (20 mL) and saturated NaCl (20 mL). The organic layer was dried over anhydrous MgSO4, 
filtered and concentrated to yield the crude product as a red solid (622 mg). Purification by flash column 
chromatography on silica gel (hexanes/EtOAc, 1:1) gave the title compound as yellow oil (315 mg, 61%). Rf 
(hexanes/EtOAc, 1:1) = 0.14; 1H NMR (500 MHz, CDCl3): δ = 7.20 (dt, J = 15.7, 6.8 Hz, 1H), 5.93 (dt, J = 
15.7, 1.6 Hz, 1H), 5.82 (sep, J = 6.1 Hz, 1H), 4.51 (s, 1H), 3.15 – 3.09 (m, 2H), 2.28 (dq, J = 7.1, 1.6 Hz, 
2H), 1.54 – 1.47 (m, 4H), 1.44 (s, 9H), 1.39 – 1.34 (m, 2H); 13C NMR (125.8 MHz, CDCl3): δ = 163.0, 
156.1, 154.9, 120.7 (q, 1JCF = 282.1 Hz), 118.2, 79.3, 66.5 (sep, 2JCF = 34.2 Hz), 40.5, 32.7, 30.1, 28.6, 27.5, 
26.5; HRMS (ESI): m/z [M+Na]+ calcd for C16H23F6NO4Na+: 430.1424, found: 430.1428. 
 
4.1.11. 1,1,1,3,3,3-Hexafluoropropan-2-yl 7-((di-tert-butoxycarbonyl)amino)-3-(tritylthio)heptanoate (23) 
To a stirred solution of HFIP-ester 21 (124 mg, 0.25 mmol) in dry CH2Cl2 (5 mL) was added Et3N (0.14 mL, 
1.00 mmol) and triphenylmethanethiol (339 mg, 1.23 mmol). The reaction mixture was stirred at room 
temperature for 69 h and then diluted with CH2Cl2 (30 mL), washed with H2O (40 mL), dried over anhydrous 
MgSO4 and concentrated to give the crude product as yellow oil (427 mg). Purification by flash column 
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chromatography on silica gel (hexanes/EtOAc, 95:5) gave the title compound (101 mg, 52%). Rf  
(hexanes/EtOAc, 95:5) = 0.12; 1H NMR (600 MHz, CDCl3): δ = 7.54 – 7.51 (m, 6H), 7.30 – 7.27 (m, 6H), 
7.22 – 7.19 (m, 3H), 5.61 (sep, J = 6.1 Hz, 1H), 3.51 (t, J = 7.5 Hz, 2H), 2.70 – 2.65 (m, 1H), 2.20 (dd, J = 
16.7, 9.8 Hz, 1H), 1.80 (dd, J = 16.8, 3.4 Hz, 1H), 1.59 – 1.44 (m, 4H), 1.50 (s, 18H), 1.41 – 1.25 (m, 2H); 
13C NMR (150.9 MHz, CDCl3): δ = 168.3, 152.8, 144.7, 129.5, 128.2, 126.9, 120.4 (q, 1JCF = 282.2 Hz), 
82.2, 67.7, 66.1 (sep, 2JCF = 34.6 Hz), 46.2, 40.7, 38.4, 34.3, 29.1, 28.2, 23.6; HRMS (ESI): m/z [M+Na]+ 
calcd for C39H45F6NO6SNa+: 792.2764; found: 792.2767. 
 
4.1.12. 1,1,1,3,3,3-Hexafluoropropan-2-yl 8-((tert-butoxycarbonyl)amino)-3-(tritylthio)octanoate (24) 
To a stirred solution of unsaturated HFIP ester 22 (315 mg, 0.77 mmol) in dry CH2Cl2 (5 mL) was added 
triphenylmethanethiol (641 mg, 2.32 mmol) and Et3N (0.32 mL, 2.39 mmol). The reaction mixture was 
stirred at room temperature for 48 h and then diluted with CH2Cl2 (30 mL) and washed with H2O (40 mL). 
The organic layer was dried over anhydrous MgSO4, filtered and concentrated to give the crude product as 
yellow oil (958 mg). Purification by flash column chromatography on silica gel (hexanes/EtOAc, 9:1) gave 
the title compound as yellow foam (483 mg, 91%). Rf (hexanes/EtOAc, 9:1) = 0.19; 1H NMR (500 MHz, 
CDCl3): δ = 7.53 – 7.51 (m, 6H), 7.30 – 7.27 (m, 6H), 7.22 – 7.19 (m, 3H), 5.61 (sep, J = 6.1 Hz, 1H), 4.47 
(bs, 1H), 3.15 – 3.01 (m, 2H), 2.69 – 2.66 (m, 1H), 2.22 (dd, J = 16.6, 9.9 Hz, 1H), 1.83 (dd, J = 16.6, 3.4 
Hz, 1H), 1.55 – 1.48 (m, 2H), 1.45 (s, 9H), 1.44 – 1.31 (m, 4H), 1.23 – 1.16 (m, 2H); 13C NMR (125.8 MHz, 
CDCl3): δ = 168.3, 156.1, 144.7, 129.6, 128.2, 126.9, 120.4 (q, 1JCF = 282.5 Hz), 79.2, 67.7, 66.2 (sep, 2JCF = 
34.8 Hz), 40.7 (2C), 38.5, 34.6, 30.0, 28.6, 26.8, 26.0; HRMS (ESI): m/z [M+Na]+ calcd for 
C35H39F6NO4SNa+: 706.2396; found: 706.2402. 
 
 
4.1.13. 7-((Di-tert-butoxycarbonyl)amino)-3-(tritylthio)heptanoic acid (25) 
To a stirred solution of Michael product 23 (448 mg, 0.58 mmol) in THF (2 mL) was added LiOH (1 M, 4 
mL, 4 mmol). The reaction mixture was stirred at room temperature for 17 h. The solvent was removed under 
reduced pressure and the pH of the aqueous residue was acidified to pH ~ 4 with 10% citric acid. The 
mixture was extracted with CH2Cl2 (4 x 10 mL) and the combined organic layer was washed with saturated 
NaCl (25 mL), dried over anhydrous MgSO4 and concentrated to give the crude product as yellow oil (321 
mg, 33%). Purification by flash column chromatography on silica gel (CH2Cl2/MeOH, 95:5) gave the title 
compound as a colorless oil (116 mg). Rf (CH2Cl2/MeOH, 95:5) = 0.30; 1H NMR (500 MHz, CDCl3): δ  = 
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7.53 – 7.50 (m, 6H), 7.29 – 7.25 (m, 6H), 7.21 – 7.17 (m, 3H), 3.48 (t, J = 7.4 Hz, 2H), 2.68 – 2.62 (m, 1H), 
2.17 (dd, J = 16.4, 9.0 Hz, 1H), 1.93 (16.4, 4.2 Hz, 1H), 1.49 (s, 18H), 1.46 – 1.35 (m, 4H), 1.34 – 1.21 (m, 
2H); 13C NMR (125.8 MHz, CDCl3): δ = 176.8, 152.8, 144.9, 129.7, 128.1, 126.8, 82.3, 67.7, 46.4, 41.0, 
39.2, 34.5, 29.1, 28.2, 23.6; HRMS (ESI): m/z [M+Na]+ calcd for C36H45NO6SNa+: 642.2860; found: 
642.2868. 
 
4.1.14. 8-((tert-Butoxycarbonyl)amino)-3-(tritylthio)octanoic acid (26) 
To a stirred solution of HFIP ester 24 (201 mg, 0.30 mmol) in THF (10 mL) was added LiOH (1 M, 2.0 mL, 
2.0 mmol). The reaction mixture was stirred at room temperature for 24 h. The solvent was removed under 
reduced pressure and the residue was acidified to pH 4 with 10% citric acid. The mixture was extracted with 
CH2Cl2 (4 x 25 mL) and the combined organic layer was washed with saturated NaCl (50 mL), dried over 
anhydrous MgSO4, filtered and concentrated to give the crude product as yellow foam (309 mg). Purification 
by flash column chromatography on silica gel (CH2Cl2/MeOH, 95:5) gave the title compound as yellow foam 
(197 mg, 56%). Retains CH2Cl2. Rf (CH2Cl2/MeOH, 95:5) = 0.28; 1H NMR (500 MHz, DMSO-d6): δ = 12.09 
(s, 1H), 7.44 – 7.42 (m, 6H), 7.36 – 7.31 (m, 6H), 7.25 – 7.22 (m, 3H), 6.73 (t, J = 5.4 Hz, 1H), 2.84 (q, J = 
6.6 Hz, 2H), 2.57 – 2.52 (m, 1H), 2.16 (dd, J = 16.3, 9.0 Hz, 1H), 1.87 (dd, J = 16.3, 4.2 Hz, 1H), 1.38 (s, 
9H), 1.29 – 1.23 (m, 4H), 1.19 – 1.07 (m, 3H), 1.03 – 0.98 (m, 2H); 13C NMR (125.8 MHz, DMSO-d6): δ = 
172.2, 155.5, 144.6, 129.1, 128.0, 126.6, 77.2, 66.9, 40.8, 39.8 (HSQC), 39.1 (HSQC), 34.1, 29.3, 28.3, 26.2, 
25.3; HRMS (ESI): m/z [M+Na]+ calcd for C32H39NO4SNa+: 556.2492; found: 556.2499.  
 
4.1.15. tert-Butyl (3-(naphthalene-2-yl)propyl)carbamate (28) 
N-Boc allylamine 27 (1.02 g, 6.5 mmol) was dissolved in dry THF (6.0 mL) and 9-BBN (0.5 M in THF, 20.0 
mL, 10.0 mmol) was added. The resulting mixture was stirred at room temperature for 2.5 h before 2-
bromonaphthalene (1.35 g, 6.5 mmol), Pd(dppf)2Cl2 Ŋ CH2Cl2 (308 mg, 0.4 mmol) and NaOH (1 M, 10.0 mL, 
10.0 mmol) were added. The reaction mixture was stirred at room temperature for 3 h, then degassed and 
additional Pd(dppf) 2Cl2 Ŋ CH2Cl2 (55 mg, 0.07 mmol) was added. The reaction mixture was stirred for 14 h 
at room temperature before saturated NH4Cl (40 mL) was added. The resulting mixture was extracted with 
EtOAc (4 x 25 ml) and the combined organic layer was dried over MgSO4, filtered and concentrated to yield 
the crude product as brown oil (3.28 g). Purification by flash column chromatography on silica gel 
(hexanes/EtOAc 8.5:1.5 and second column using hexanes/EtOAc 8:2, respectively) gave a white solid (1.36 
g), which still contained minor impurities (1H NMR). To a solution of the solid material (818 mg out of 1.36 
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g) in THF (20 mL), NaOH (15%, 5.0 mL) and H2O2 (30%, 10.0 mL) were added and the resulting mixture 
was stirred at 0 °C for 2 h. Dilution with diethyl ether (20 mL) followed by washing with saturated NaHCO3 
(20 mL) and saturated NaCl (20 mL) before the organic layer was dried over anhydrous MgSO4, filtered and 
concentrated to give a yellow oil (785 mg). Purification by flash column chromatography on silica gel 
(hexanes/EtOAc, 8.5:1.5) gave the title compound (774 mg, 70%). Rf (hexanes/EtOAc, 8.5:1.5) = 0.24; 1H 
NMR (600 MHz, CDCl3): δ = 7.82 – 7.76 (m, 3H), 7.62 (s, 1H), 7.47 – 7.41 (m, 2H), 7.32 (dd, J = 8.4, 1.2 
Hz, 1H), 4.56 (bs, 1H), 3.24 – 3.15 (m, 2H), 2.81 (t, J = 7.8 Hz, 2H), 1.90 (p, J = 7.5 Hz, 2H), 1.46 (s, 9H); 
13C NMR (150.9 MHz, CDCl3): δ = 156.1, 139.2, 133.7, 132.2, 128.1, 127.7, 127.5, 127.3, 126.5, 126.1, 
125.3, 79.3, 40.5, 33.4, 31.8, 28.6; HRMS (ESI): m/z [M+Na]+ calcd for C18H23NO2Na+: 308.1621; found: 
308.1628. 
 
4.1.16. N-(2,2-Dimethoxyethyl)-3-(naphthalen-2-yl)propan-1-amine (29) 
To a stirred solution of 28 (321 mg, 1.12 mmol) in CH2Cl2 (5 mL) at 0 °C was added TFA (4.0 mL). The 
reaction mixture was stirred at room temperature for 2.5 h, after which the solvent was removed under 
reduced pressure. The residue was suspended in 10% NaOH (15 mL) and extracted with CH2Cl2 (4 x 20 mL). 
The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated to give the crude 
product as brown oil (192 mg), which was used in the next step without purification. To a stirred solution of 
crude 3-(naphthalene-2-yl)propan-1-amine (192 mg) in anhydrous DMF (5 mL) was added 
bromoacetaldehyde dimethyl acetal (0.18 mL, 1.52 mmol) and K2CO3 (0.145 g, 1.05 mmol). The reaction 
mixture was stirred for 27.5 h at 80 °C. The mixture was diluted with H2O (20 mL) and extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with saturated NaCl (20 mL), dried over 
anhydrous MgSO4, filtered and concentrated to give the crude product as yellow oil (572 mg). Purification by 
flash column chromatography on silica gel (CH2Cl2/MeOH/NH4OH, 95:4.5:0.5) gave the title compound as 
pale yellow oil (96 mg, 31%). Rf (CH2Cl2/MeOH/NH4OH, 95:4.5:0.5) = 0.31; 1H NMR (400 MHz, CDCl3): δ 
= 7.82 – 7.74 (m, 3H), 7.61 (s, 1H), 7.47 – 7.38 (m, 2H), 7.33 (dd, J = 8.4, 1.7 Hz, 1H), 4.47 (t, J = 5.5 Hz, 
1H), 3.37 (s, 6H), 2.81 (t, J = 7.5 Hz, 2H), 2.73 (d, J = 5.5 Hz, 2H), 2.69 (t, J = 7.2 Hz, 2H), 1.92 (p, J = 7.6 
Hz, 2H), 1.65 (bs, 1H); 13C NMR (100.6 MHz, CDCl3): δ = 139.6, 133.7, 132.1, 128.0, 127.7, 127.5, 127.4, 
126.4, 126.0, 125.2, 103.9, 54.2, 51.2, 49.5, 33.8, 31.6; HRMS (ESI): m/z [M+H]+ calcd for C17H24NO2+: 
274.1802; found: 274.1809. 
 
4.1.17. (9H-Fluoren-9-yl)methyl (S)-(1-((2,2-dimethoxyethyl)(3-(naphthalen-2- yl)propyl)amino)-1-oxo-5-
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(3-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentan-2-yl)carbamate (30) 
To a stirred solution of 29 (96 mg, 0.35 mmol) in dry CH2Cl2 (2 mL) was added Fmoc-Arg(Pbf)-OH (244 
mg, 0.38 mmol), HATU (136 mg, 0.36 mmol) and DIPEA (0.20 mL, 1.15 mmol). The resulting mixture was 
stirred for 25 h at room temperature. The solvent was removed under reduced pressure and the residue was 
partitioned between H2O (10 mL) and EtOAc (10 mL). The aqueous layer was extracted with EtOAc (3 x 20 
mL) and the combined organic layer was washed with 1 M KHSO4 (20 mL), H2O (20 mL), saturated 
NaHCO3 (20 mL) and saturated NaCl (20 mL), dried over anhydrous MgSO4, filtered and concentrated to 
give the crude product (341 mg). Purification by flash column chromatography on silica gel (EtOAc/hexanes, 
8:2) gave the title compound (250 mg, 79%). Rf (EtOAc/hexanes, 8:2) = 0.10; NMR analyses did not give 
useful information due to formation of rotamers; HRMS (ESI): m/z [M+H]+ calcd for C51H62N5O8S+: 
904.4315; found: 904.4314; m/z [M+Na]+ calcd for C51H61N5O8SNa+: 926.4133; found: 926.4139. 
 
4.1.18. General protocol A: Fmoc-deprotection 
To a stirred solution of the Fmoc-protected amine (0.06 M in CH2Cl2) was added Et2NH (50 equiv) and the 
resulting mixture was stirred at room temperature for 2-3 h (monitored by TLC). The solvent was removed 
under reduced pressure and the residue was used in the next step without purification. 
 
4.1.19. General protocol B: Formation of linear precursors 
HATU (165 mg, 0.43 mmol) and DIPEA (0.19 mL, 1.1 mmol) were added to a stirred solution the carboxylic 
acid (6, 11, 25 or 26) carrying the R1 side chain (0.36 mmol) in dry CH2Cl2 (2 mL) and the reaction mixture 
was stirred at room temperature for 20 minutes. Fmoc-deprotected amine 30 or 31 (see general protocol A, 
0.56 mmol) in dry CH2Cl2 (12 mL) was then added and stirring was continued for 24 h. The solvent was 
evaporated, and the resulting red residue was partitioned between H2O (10 mL) and EtOAc (10 mL). The 
aqueous layer was further extracted with EtOAc (3 x 10 mL) and the combined organic layers were washed 
with 1 M KHSO4 (20 mL), H2O (20 mL), saturated NaHCO3 (20 mL) and saturated NaCl (20 mL). The 






The title compound was prepared from carboxylic acid 6 (177 mg, 0.36 mmol) which was dissolved in DMF 
(2 mL) and Fmoc-deprotected amine 31 (see general protocol B, 0.56 mmol) following general protocol A. 
The crude product (red foam, 510 mg) was purified by flash column chromatography on silica gel 
(EtOAc/hexane; 7.5:2.5 to 9.5:0.5 followed by EtOAc) to give an inseparable mixture of diastereoisomers of 
32 (174 mg, 42%). Rf (EtOAc) = 0.7; NMR analyses did not give useful information due to formation of 
rotamers; HRMS (ESI): m/z [M+H]+ calcd for C64H81N6O9S2+: 1141.5501; found: 1141.5502; m/z [M+Na]+ 




(tritylthio)hexyl)carbamate (33)  
The title compound was prepared from carboxylic acid 11 (160 mg, 0.32 mmol) and Fmoc-deprotected amine 
31 (see general protocol B, 0.45 mmol) following general protocol A. The crude product (red foam, 654 mg) 
was purified by flash column chromatography on silica gel (EtOAc/hexane; 8:2) to give an inseparable 
mixture of diastereoisomers of 33 (216 mg, 59%). Rf (EtOAc/hexanes, 8:2) = 0.19; NMR analyses did not 
give useful information due to formation of rotamers; HRMS (ESI): m/z [M+H]+ calcd for C65H83N6O9S2+: 





The title compound was prepared from carboxylic acid 25 (116 mg, 0.19 mmol) and Fmoc-deprotected amine 
31 (see general protocol B, 0.44 mmol) following general protocol A. The crude product (red oil, 444 mg) 
was purified by flash column chromatography on silica gel (EtOAc/hexanes, 8:2) to give an inseparable 
mixture of diastereoisomers of 34 as a colorless oil (47 mg, 20%). Rf (EtOAc/hexanes, 8:2) = 0.57; NMR 
analyses did not give useful information due to formation of rotamers; HRMS (ESI): m/z [M+Na]+ calcd for 






The title compound was prepared from carboxylic acid 26 (105 mg, 0.20 mmol) and Fmoc-deprotected amine 
31 (see general protocol B, 0.10 mmol) following general protocol A. The crude product (205 mg) was 
purified by flash column chromatography on silica gel (EtOAc/hexanes, 9:1) to give an inseparable mixture 
of diastereoisomers of 35 as a colorless oil (80 mg, 68%). Rf (EtOAc/hexanes, 9:1) = 0.25; NMR analyses did 
not give useful information due to formation of rotamers; HRMS (ESI): m/z [M+Na]+ calcd for 





The title compound was prepared from carboxylic acid 11 (166 mg, 0.33 mmol) and Fmoc-deprotected amine 
30 (see general protocol B, 0.10 mmol) following general protocol A. The crude product (273 mg) was 
purified by flash column chromatography on silica gel (EtOAc/hexane, 9:1) to give an inseparable mixture of 
diastereoisomers of 36 as a colorless oil (90 mg, 73%). Rf (EtOAc/hexanes, 9:1) = 0.35; NMR analyses did 
not give useful information due to formation of rotamers; HRMS (ESI): m/z [M+Na]+ calcd for 





The title compound was prepared from carboxylic acid 27 (93 mg, 0.17 mmol) and Fmoc-deprotected amine 
30 (see general protocol B, 0.13 mmol) following general protocol A. The crude product (238 mg) was 
purified by flash column chromatography on silica gel (EtOAc/hexane, 8:2) to give an inseparable mixture of 
diastereoisomers of 36 as a colorless oil (117 mg, 77%). Rf (EtOAc/hexanes, 8:2) = 0.22; NMR analyses did 
not give useful information due to formation of rotamers; HRMS (ESI): m/z [M+H]+ calcd for 
C68H89N6O9S2+: 1197.6127; found: 1197.6134; m/z [M+Na]+ calcd for C68H88N6O9S2Na+: 1219.5946; found: 
1219.6000. 
 
4.1.26. General procedure C: Global deprotection and cyclization 
The linear precursor was dissolved in a mixture of TFA, thioanisole and H2O (90:5:5, 100 mL per mmol) and 
the resulting mixture was stirred at room temperature for 2-4 h. The TFA was removed under reduced 
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pressure and the crude product was precipitated by addition of cold diethyl ether. The diethyl ether was 





Linear precursor 32 (174 mg, 0.15 mmol) was deprotected and cyclized following general procedure C. The 
crude product (approx. 200 mg) was dissolved in dry DMF (5 mL) and 1H-pyrazole-1-carboxamidine 
hydrochloride (305 mg, 2.06 mmol) and DIPEA (0.58 mL, 3.33 mmol) were added and the mixture was 
stirred under inert atmosphere for 70 h during which the reaction was monitored by RP-HPLC. Diethyl ether 
(20 mL) was then added and the mixture was cooled at 4 °C and stirred for an additional hour, resulting in 
the precipitation of a white solid. The crude product was purified by semi-preparative RP-HPLC to give the 
title compound as a fluffy white solid (24 mg, 42%). 1H NMR (600 MHz, CD3OD): δ = 7.86 – 7.83 (m, 2H), 
7.80 (d, J = 8.3 Hz, 1H), 7.64 (s, 1H), 7.50 – 7.44 (m, 2H), 7.42 (dd, J = 8.5, 1.5 Hz, 1H), 5.07 (dd, J = 10.0, 
5.4 Hz, 1H), 5.01 (dd, J = 8.8, 4.2 Hz, 1H), 3.72 – 3.69 (m, 2H), 3.43 (dd, J = 12.8, 4.3 Hz, 1H), 3.29 – 3.25 
(m, 1H), 3.22 – 3.16 (m, 1H), 3.15 – 3.03 (m, 5H), 2.86 – 2.80 (m, 1H), 2.59 (dd, J = 16.4, 3.6 Hz, 1H), 2.49 
(dd, J = 16.4, 11.9 Hz, 1H), 1.87 – 1.72 (m, 3H), 1.70 – 1.64 (m, 1H), 1.52 – 1.44 (m, 2H); 13C NMR (150.9 
MHz, CD3OD): δ = 170.8, 169.2, 158.6, 158.5, 137.5, 135.0, 133.8, 129.4, 128.7, 128.64, 128.59, 128.5, 
127.3, 126.8, 56.6, 53.1, 52.1, 49.7, 41.7, 41.6, 39.8, 35.3, 35.2, 34.1, 29.3 26.2; HRMS (ESI): m/z [M+H]+ 




Bicycle 44b was prepared as described for 44a above. The crude product was purified by semi-preparative 
RP-HPLC to give the title compound as a fluffy white solid (22 mg, 38%). 1H NMR (600 MHz, CD3OD): δ = 
7.84 – 7.78 (m 3H), 7.71 (s, 1H), 7.48 – 7.42 (m, 3H), 5.38 (dd, J = 4.0, 2.8 Hz, 1H), 4.65 (app t, J = 7.8 Hz, 
1H), 4.20 (dt, J = 13.4, 7.7 Hz, 1H), 3.98 (dd, J = 15.0, 4.4 Hz, 1H), 3.69 – 3.65 (m, 1H), 3.54 (dd, J = 15.0, 
2.5 Hz, 1H), 3.49 – 3.44 (m ,1H), 3.17 (app t, J = 7.0 Hz, 2H), 3.13 – 3.04 (m, 3H), 2.99 – 2.90 (m, 2H), 2.61 
(dd, J = 14.8, 3.9 Hz, 1H), 1.84 – 1.77 (m, 1H), 1.60 – 1.45 (m, 3H), 1.35 – 1.23 (m, 2H); 13C NMR (150.9 
MHz, CD3OD); δ = 172.3, 169.4, 158.6, 158.4, 137.2, 135.0, 133.9, 129.3, 128.7, 128.54, 128.45 (2C), 
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127.2, 126.7, 56.1, 55.1, 49.2 (HSQC), 48.5 (HSQC), 41.4, 40.02, 39.98, 38.1, 37.8, 34.6, 30.6, 26.1; HRMS 




Linear precursor 39 (128 mg, 111 mmol) was deprotected and cyclized following general procedure C. The 
crude product (58 mg) was dissolved in anhydrous DMF (4 mL) and 1H-pyrazole-1-carboxamidine 
hydrochloride (27 mg, 0.18 mmol) and DIPEA (30 µL, 0.17 mmol) were added. The reaction mixture was 
stirred under inert atmosphere for 144 h during which the reaction was monitored by analytical RP-HPLC. 
Additional 1H-pyrazole-1-carboxamidine hydrochloride and DIPEA was added during this time. Diethyl 
ether (25 mL) was added and the mixture was cooled to 0 °C and stirred for an additional hour, resulting in 
the precipitation of a yellow solid (203 mg). The crude product was purified by semi-preparative RP-HPLC 
to give the title compound as a fluffy white solid (6.5 mg, 15%). 1H NMR (600 MHz, CD3OD): δ = 7.86 – 
7.82 (m, 2H), 7.81 – 7.77 (m, 1H), 7.62 (s, 1H), 7.51 – 7.44 (m, 2H), 7.44 – 7.40 (m, 1H), 5.15 (dd, J = 10.1, 
5.1 Hz, 1H), 4.89 (HSQC, 1H), 3.88 – 3.81 (m, 1H), 3.58 – 3.50 (m, 1H), 3.31 (HSQC, 1H), 3.22 – 3.08 (m, 
5H), 3.07 – 2.99 (m, 2H), 2.53 – 2.44 (m, 2H), 2.41 – 2.33 (m, 1H), 1.94 – 1.86 (m, 1H), 1.81 – 1.73 (m, 1H), 
1.57 – 1.27 (m, 6H); 13C NMR (150.9 MHz, CD3OD): δ = 170.7, 169.2, 158.62, 158.57, 137.7, 135.0, 133.8, 
129.4, 128.71, 128.68, 128.67, 128.63, 127.4, 126.8, 56.6, 54.1, 51.7, 49.9, 42.2, 42.0, 41.6, 37.0, 34.1, 33.0, 
29.1, 27.2, 26.2; HRMS (ESI): m/z [M+2H]2+ calcd for C27H40N8O2S2+: 270.1492; found 270.1499. Purity = 




Bicycle 45b was prepared as described for 45a. The crude product was purified by semi-preparative RP-
HPLC gave the title compound as a fluffy white solid (6.6 mg, 16%). 1H NMR (600 MHz, CD3OD): δ = 7.83 
– 7.78 (m, 3H), 7.71 (s, 1H), 7.49 – 7.42 (m, 3H), 5.35 – 5.33 (m, 1H), 4.66 (t, J = 7.8 Hz, 1H), 4.20 – 4.14 
(m, 1H), 3.95 (dd, J = 14.8, 4.3 Hz, 1H), 3.64 – 3.58 (m, 1H), 3.53 (dd, J = 14.9, 2.8 Hz, 1H), 3.51 – 3.46 (m, 
1H), 3.13 – 2.92 (m, 7H), 2.59 (dd, J = 14.9, 3.8 Hz, 1H), 1.62 – 1.47 (m, 5H), 1.40 – 1.28 (m, 3H); 13C 
NMR (150.9 MHz, CD3OD): δ = 172.6, 169.5, 158.6, 158.5, 137.2, 135.0, 133.9, 129.3, 128.7, 128.51, 
128.45, 128.4, 127.2, 126.7, 56.1, 55.0, 49.2 (HSQC), 48.8 (HSQC), 42.0, 41.5, 40.4, 40.2, 36.2, 34.6, 30.6, 
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27.5, 26.2; HRMS (ESI): m/z [M + 2H]2+ calcd for C27H40N8O2S2+: 270.1492; found 270.1498. Purity = 95.2 




Linear precursor 40 (47 mg, 0.04 mmol) was deprotected and cyclized following general procedure C. The 
crude product (29 mg) was dissolved in anhydrous DMF (2 mL) and 1H-pyrazole-1-carboxamidine 
hydrochloride (85 mg, 0.58 mmol) and DIPEA (0.1 mL, 0.57 mmol) were added. The reaction mixture was 
stirred under inert atmosphere for 94 h during which the reaction was monitored by analytical RP-HPLC. 
Cold diethyl ether (10 mL) was then added and the mixture was cooled at 0 °C and stirred for an additional 
hour, resulting in the precipitation of a white solid. The crude product was purified by semi-preparative RP-
HPLC to give the title compound as fluffy white solid (3.3 mg, 22%). 1H NMR (850 MHz, CD3OD): δ = 7.84 
(t, J = 8.4 Hz, 2H), 7.79 (d, J = 8.0 Hz, 1H), 7.61 (s, 1H), 7.50 – 7.45 (m, 2H), 7.41 (dd, J = 8.3, 1.8 Hz, 1H), 
5.16 (dd, J = 10.4, 5.0 Hz, 1H), 4.88 (HSQC, 1H), 3.88 – 3.84 (m, 1H), 3.52 – 3.47 (m, 1H), 3.27 (dd, J = 
12.6, 4.3 Hz, 1H), 3.21 – 3.11 (m, 5H), 3.06 – 3.02 (m, 1H), 2.98 (dd, J = 12.6, 9.9 Hz, 1H), 2.48 (dd, J = 
16.3, 3.1 Hz, 1H), 2.45 – 2.41 (m, 1H), 2.35 (dd, J = 16.3, 11.9 Hz, 1H), 1.93 – 1.88 (m, 1H), 1.81 – 1.75 (m, 
1H), 1.56 – 1.45 (m, 4H), 1.44 – 1.38 (m, 1H), 1.37 – 1.28 (m, 2H), 1.20 – 1.14 (m, 1H); 13C NMR (213.8 
MHz, CD3OD): δ = 170.8, 169.3, 158.7, 158.6, 137.7, 135.0, 133.8, 129.4, 128.70, 128.69 (2C), 128.63, 
127.4, 126.8, 56.6, 54.3, 51.6, 50.0, 42.3, 42.2, 41.6, 37.0, 35.5, 34.0, 29.5, 29.0, 26.2, 24.8; HRMS (ESI): 




Bicycles 46b was prepared as described for 46a above. The crude product was purified by semi-preparative 
RP-HPLC to give the title compounds as a fluffy white solid (3.6 mg, 2:8 mixture between 46c+d and 46b). 
1H NMR (850 MHz, CD3OD): 7.83 – 7.78 (m, 3H), 7.71 (s, 1H), 7.48 – 7.42 (m, 3H), 5.32 (t, J = 3.6 Hz, 
1H), 4.67 (t, J = 7.8 Hz, 1H), 4.16 (dt, J = 13.7, 7.7 Hz, 1H), 3.93 (dd, J = 14.8, 4.3 Hz, 1H), 3.60 – 3.56 (m, 
1H), 3.53 – 3.45 (m, 2H), 3.14 – 3.04 (m, 4H), 3.00 – 2.93 (m, 3H), 2.58 (dd, J = 14.9, 3.9 Hz, 1H), 1.68 – 
1.48 (m, 5H), 1.42 – 1.29 (m, 5H); 13C NMR (213.8 MHz, CD3OD): δ = 172.7, 169.6, 158.6, 158.5, 137.2, 
135.0, 133.9, 129.3, 128.7, 128.51, 128.46, 128.43, 127.2, 126.7, 56.1, 54.9, 49.0 (2C, HSQC), 42.2, 41.5, 
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40.6, 40.3, 38.7, 34.6, 30.6, 29.5, 26.2, 25.1; HRMS (ESI) m/z [M+H]+ calcd for C28H41N8O2S+: 553.3068; 
found: 553.3075. 
Due to signal overlap, all chemical shifts could not be unambiguously identified for 46c. See supporting 




Linear precursor 41 (80 mg, 0.07 mmol) was deprotected and cyclized following general procedure C. The 
crude product (108 mg) was dissolved in anhydrous DMF (5 mL) and 1H-pyrazole-1-carboxamidine 
hydrochloride (118 mg, 0.80 mmol) and DIPEA (0.11 mL, 0.63 mmol) were added. The reaction mixture 
was stirred under inert atmosphere for 99 h during which the reaction was monitored by analytical RP-HPLC. 
Cold diethyl ether (20 mL) was then added and the mixture was cooled at 4 °C and stirred for an additional 
hour, resulting in the precipitation of a white solid. The crude product was purified by semi-preparative RP-
HPLC to give the title compound as fluffy white solid (3.5 mg, 13%). 1H NMR (850 MHz, CD3OD): δ = 7.84 
(t, J = 7.7 Hz, 2H), 7.79 (d, J = 7.9 Hz, 1H), 7.62 (s, 1H), 7.50 – 7.45 (m, 2H), 7.41 (dd, J = 8.4, 1.7 Hz, 1H), 
5.16 (dd, J = 10.3, 5.1 Hz, 1H), 4.86 (HSQC, 1H), 3.89 – 3.85 (m, 1H), 3.51 – 3.47 (m, 1H), 3.27 (dd, J = 
12.6, 4.4 Hz, 1H), 3.21 – 3.11 (m, 5H), 3.05 – 3.02 (m, 1H), 2.97 (dd, J = 12.6, 10.0 Hz, 1H), 2.48 (dd, J = 
16.4, 3.1 Hz, 1H), 2.43 – 2.38 (m, 1H), 2.33 (dd, J = 16.3, 11.9 Hz, 1H), 1.94 – 1.88 (m, 1H), 1.81 – 1.75 (m, 
1H), 1.59 – 1.48 (m, 4H), 1.41 – 1.36 (m, 1H), 1.34 – 1.25 (m, 4H), 1.17 – 1.10 (m, 1H); 13C NMR (213.8 
MHz, CD3OD): δ = 170.8, 169.3, 158.7, 158.6, 137.7, 135.0, 133.8, 129.4, 128.71, 128.692, 128.688, 128.64 
, 127.4, 126.8, 56.6, 54.4, 51.6, 50.0, 42.4, 42.3, 41.6, 37.1, 35.8, 34.0, 29.7, 29.0, 27.37, 27.36, 26.2; HRMS 




Bicycles 47b and was prepared as described for 47a above. The crude product was purified by semi-
preparative RP-HPLC to give the title compounds as a fluffy white solid (3.5 mg, 13%). 1H NMR (850 MHz, 
CD3OD): δ = 7.84 – 7.78 (m, 3H), 7.71 (s, 1H), 7.48 – 7.42 (m, 3H), 5.31 (t, J = 3.7 Hz, 1H), 4.67 (t, J = 7.8 
Hz, 1H), 4.18 – 4.13 (m, 1H), 3.92 (dd, J = 14.8, 4.3 Hz, 1H), 3.59 – 3.55 (m, 1H), 3.52 – 3.48 (m, 2H), 3.17 
– 3.11 (m, 2H), 3.11 – 3.05 (m, 2H), 3.01 – 2.94 (m, 3H), 2.57 (dd, J = 14.9, 4.0 Hz, 1H), 1.61 – 1.49 (m, 
5H), 1.39 – 1.29 (m, 7H); 13C NMR (213.8 MHz, CD3OD): δ = 172.7, 169.5, 158.6, 158.5, 137.2, 135.0, 
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133.9, 129.3, 128.7, 128.51, 128.46, 128.43, 127.2, 126.7, 56.0, 54.8, 49.2 (HSQC), 49.1 (HSQC), 42.3, 
41.5, 40.6, 40.4, 39.1, 34.6, 30.6, 29.7, 27.6, 27.3, 26.2; HRMS (ESI): m/z [M + H]+ calcd for C29H43N8O2S+: 




Linear precursor 42 (90 mg, 0.08 mmol) was deprotected and cyclized following general procedure C. The 
crude product (97 mg) was dissolved in anhydrous DMF (2 mL) and 1H-pyrazole-1-carboxamidine 
hydrochloride (85 mg, 0.58 mmol) and DIPEA (0.10 mL, 0.57 mmol) were added. The reaction mixture was 
stirred under inert atmosphere for 78 h during which the reaction was monitored by analytical RP-HPLC. 
Cold diethyl ether (10 mL) was then added and the mixture was cooled at 4 °C and stirred for an additional 
hour, resulting in the precipitation of a white solid. The crude product was purified by semi-preparative RP-
HPLC to give the title compound as fluffy white solid (3.3 mg, 11%). 1H NMR (850 MHz, CD3OD): δ = 7.82 
– 7.78 (m, 2H), 7.76 (d, J = 8.3 Hz, 1H), 7.69 (s, 1H), 7.46 – 7.41 (m, 2H), 7.37 (dd, J = 8.4, 1.8 Hz, 1H), 
5.01 (dd, J = 10.1, 5.0 Hz, 1H), 4.95 (dd, J = 8.4, 4.7 Hz, 1H), 3.68 – 3.63 (m, 1H), 3.54 – 3.48 (m, 2H), 3.41 
– 3.37 (m, 1H), 3.27 – 3.23 (m, 1H), 3.22 – 3.16 (m, 3H), 3.02 – 2.98 (m, 1H), 2.90 – 2.86 (m, 1H), 2.84 – 
2.80 (m, 1H), 2.58 (dd, J = 16.6, 3.4 Hz, 1H), 2.42 (dd, J = 16.5, 12.0 Hz, 1H), 2.11 – 2.03 (m, 2H), 1.97 – 
1.92 (m, 1H), 1.80 – 1.74 (m, 1H), 1.71 – 1.65 (m, 1H), 1.64 – 1.57 (m, 4H), 1.52 – 1.47 (m, 1H); 13C NMR 
(213.8 MHz, CD3OD): δ = 170.9, 169.2, 158.7, 158.6, 140.5, 135.1, 133.6, 129.1, 128.7, 128.5, 128.1, 127.4, 
127.1, 126.4, 56.7, 52.6, 52.3, 48.3, 42.1, 42.0, 41.7, 37.1, 34.5, 33.3, 29.7, 28.9, 27.2, 26.4; HRMS (ESI): 




Bicycle 48b was prepared as described for 48a above. The crude product was purified by semi-preparative 
RP-HPLC to give the title compound as a fluffy white solid (4.6 mg, 2:8 mixture between 48c and 48b). 1H 
NMR (850 MHz, CD3OD): δ = 7.82 – 7.77 (m, 3H), 7.68 (s, 1H), 7.46 – 7.40 (m, 2H), 7.40 – 7.37 (m, 1H), 
5.41 – 5.40 (m, 1H), 4.79 – 4.76 (m, 1H), 4.11 (dd, J = 14.9, 4.3 Hz, 1H), 3.67 – 3.63 (m, 1H), 3.59 – 3.55 
(m, 1H), 3.53 (dd, J = 15.0, 2.7 Hz, 1H), 3.52 – 3.48 (m, 1H), 3.27 – 3.18 (m, 3H), 3.12 – 3.09 (m, 2H), 3.05 
(dd, J = 14.8, 6.0 Hz, 1H), 2.91 – 2.86 (m, 1H), 2.83 – 2.79 (m, 1H), 2.63 (dd, J = 14.9, 3.8 Hz, 1H), 2.09 – 
1.97 (m, 2H), 1.83 – 1.75 (m, 2H), 1.69 – 1.65 (m, 2H), 1.64 – 1.57 (m, 3H), 1.46 – 1.39 (m, 1H); 13C NMR 
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(850 MHz, CD3OD): δ = 172.7, 169.9, 158.61, 158.55, 140.3, 135.2, 133.6, 129.1, 128.6, 128.4, 128.1, 
127.4, 127.0, 126.3, 56.1, 55.1, 48.4, 47.8, 42.0, 41.7, 40.4, 40.3, 36.3, 34.3, 30.7, 29.8, 27.5, 26.5; HRMS 
(ESI): m/z [M+H]+ calcd for C28H41N8O2S+: 553.3068; found: 553.3077. Purity = 97.2% (sum of 
diastereoisomers 48b and 48c, UV 220 nm) 
Due to signal overlap, all chemical shifts could not be unambiguously identified for 48c. See supporting 




Bicycle 48d was prepared as described for 48a above. The crude product was purified by semi-preparative 
RP-HPLC to give the title compound as a fluffy white solid (0.9 mg, 2:8 mixture of 48b and 48d). 1H (850 
MHz, CD3OD): δ = 7.82 – 7.77 (m, 3H), 7.68 (s, 1H), 7.45 – 7.41 (m, 2H), 7.38 (dd, J = 8.3, 1.7 Hz, 1H), 
4.66 (dd, J = 9.2, 6.0 Hz, 1H), 4.50 (dd, J = 11.4, 4.4 Hz, 1H), 3.72 – 3.68 (m, 1H), 3.67 – 3.63 (m, 1H), 3.59 
(dd, J = 13.7, 4.3 Hz, 1H), 3.49 – 3.44 (m, 1H), 3.26 – 3.19 (m, 3H), 3.16 (t, J = 6.8 Hz, 2H), 2.91 – 2.87 (m, 
1H), 2.83 – 2.79 (m, 1H), 2.62 (dd, J = 16.1, 5.3 Hz, 1H), 2.43 (dd, J = 16.2, 7.1 Hz, 1H), 2.08 – 2.00 (m, 
2H), 1.85 – 1.80 (m, 1H), 1.78 – 1.73 (m, 1H), 1.70 – 1.65 (m, 3H), 1.65 – 1.59 (m, 3H), 1.51 – 1.46 (m, 
1H); 13C (213.8 MHz, CD3OD): δ = 171.3, 170.2, 158.64, 158.59, 140.6, 135.1, 133.6, 129.0, 128.6, 128.5, 
128.3, 127.4, 127.2, 126.5, 57.4, 56.5, 48.2, 47.8, 41.9, 41.6, 41.0, 40.8, 35.1, 34.5, 31.2, 29.6, 27.3, 26.5; 
HRMS (ESI): m/z [M+H]+ calcd for C28H41N8O2S+: 553.3068; found: 553.3076. Purity = 82.7% (sum of 




Linear precursor 43 (117 mg, 0.10 mmol) was deprotected and cyclized following general procedure C. The 
crude product (87 mg) was dissolved in anhydrous DMF (5 mL), 1H-pyrazole-1-carboxamidine 
hydrochloride (100 mg, 0.69 mmol) and DIPEA (0.12 mL, 0.69 mmol) were added. The reaction mixture 
was stirred at room temperature for 93 h at room temperature during which the reaction was monitored by 
analytical RP HPLC. The reaction was cooled to 0 °C, cold diethyl ether (20 mL) was added and stirring 
continued for an additional hour, resulting in the precipitation of a brown oil (152 mg). The crude product 
was purified by semi-preparative RP-HPLC to give the title compound as a white fluffy solid (3.2 mg, 8%). 
1H NMR (850 MHz, CD3OD): δ = 7.80 (dd, J = 17.7, 8.0 Hz, 2H), 7.76 (d, J = 8.3 Hz, 1H), 7.69 (s, 1H), 
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7.46 – 7.41 (m, 2H), 7.36 (dd, J = 8.4, 1.7 Hz, 1H), 5.01 (dd, J = 10.1, 4.9 Hz, 1H), 4.91 (dd, J = 8.8, 4.5 Hz, 
1H), 3.67 (dt, J = 13.6, 7.4 Hz, 1H), 3.52 – 3.45 (m, 2H), 3.37 (ddd, J = 13.4, 7.4, 6.0 Hz, 1H), 3.27 – 3.23 
(m, 1H), 3.21 – 3.15 (m, 3H), 2.97 – 2.93 (m, 1H), 2.90 – 2.86 (m, 1H), 2.84 – 2.79 (m, 1H), 2.55 (dd, J = 
16.6, 3.4 Hz, 1H), 2.39 (dd, J = 16.6, 12.0 Hz, 1H), 2.11 – 2.03 (m, 2H), 1.97 – 1.92 (m, 1H), 1.80 – 1.74 (m, 
1H), 1.63 – 1.57 (m, 4H), 1.57 – 1.53 (m, 1H), 1.48 – 1.41 (m, 2H), 1.41 – 1.34 (m, 3H); 13C NMR (213.8 
MHz, CD3OD): δ = 171.0, 169.3, 158.65, 158.60, 140.5, 135.1, 133.5, 129.1, 128.7, 128.5, 128.1, 127.4, 
127.1, 126.3, 56.7, 52.8, 52.1, 48.3, 42.4, 42.2, 41.7, 37.3, 36.2, 34.5, 29.73, 29.67, 28.9, 27.43, 27.38, 26.3; 





Bicycles 49b was prepared as described for 49a above. The crude product was purified by semi-preparative 
RP-HPLC to give the title compound as a fluffy white solid (2.2 mg, 3:7 mixture between 49c and 49b). 1H 
NMR (850 MHz, CD3OD): δ = 7.81 – 7.77 (m, 3H), 7.69 (s, 1H), 7.46 – 7.37 (m, 3H), 5.40 – 5.39 (m, 1H), 
4.80 – 4.77 (m, 1H), 4.10 (dd, J = 14.9, 4.3 Hz, 1H), 3.67 – 3.63 (m, 1H), 3.63 – 3.59 (m, 1H), 3.53 (dd, J = 
15.0, 2.7 Hz, 1H), 3.47 – 3.43 (m, 1H), 3.27 – 3.20 (m, 2H), 3.17 (t, J = 7.2 Hz, 1H), 3.05 – 3.01 (m, 2H), 
2.92 – 2.87 (m, 1H), 2.83 – 2.78 (m, 1H), 2.62 (dd, J = 14.9, 3.8 Hz, 1H), 2.10 – 2.02 (m, 1H), 2.01 – 1.96 
(m, 1H), 1.84 – 1.75 (m, 2H), 1.70 – 1.64 (m, 2H), 1.62 – 1.56 (m, 2H), 1.47 – 1.42 (m, 1H), 1.41 – 1.24 (m, 
5H); 13C (213.8 MHz, CD3OD): δ = 172.9, 169.9, 158.6, 158.5, 140.4, 135.2, 133.6, 129.0, 128.6, 128.4, 
128.1, 127.4, 127.0, 126.3, 56.1, 55.0, 48.4, 47.7, 42.3, 41.7, 40.8, 40.5, 39.3, 34.3, 30.7, 29.9, 29.6, 27.7, 
27.3, 26.5; HRMS (ESI): m/z [M+H]+ calcd for C30H45N8O2S+: 581.3381; found: 581.3382; Purity = 96.6% 
(sum of diastereoisomers 49b and 49c, UV 220 nm). 
Due to signal overlap, all chemical shifts could not be unambiguously identified for 49c. See supporting 




Bicycle 49d was prepared as described for 49a above. The crude product was purified by semi-preparative 
RP-HPLC to give the title compound as a fluffy white solid (1.3 mg, 1:9 mixture of 49b and 49d). 1H NMR 
(850 MHz, CD3OD): δ = 7.82 – 7.77 (m, 3H), 7.68 (s, 1H), 7.46 – 7.41 (m, 2H), 7.39 (dd, J = 8.3, 1.8 Hz, 
 29 
1H), 4.65 (dd, J = 9.0, 6.1 Hz, 1H), 4.49 (dd, J = 11.4, 4.5 Hz, 1H), 3.72 – 3.68 (m, 1H), 3.66 (dd, J = 13.6, 
11.4 Hz, 1H), 3.58 (dd, J = 13.7, 4.4 Hz, 1H), 3.49 – 3.45 (m, 1H), 3.26 – 3.19 (m, 3H), 3.16 (t, J = 7.2 Hz, 
2H), 2.91 – 2.87 (m, 1H), 2.83 – 2.79 (m, 1H), 2.59 (dd, J = 16.0, 5.5 Hz, 1H), 2.41 (dd, J = 16.1, 6.9 Hz, 
1H), 2.09 – 1.99 (m, 2H), 1.85 – 1.80 (m, 1H), 1.78 – 1.72 (m, 1H), 1.70 – 1.65 (m, 2H), 1.61 – 1.56 (m, 3H), 
1.48 – 1.34 (m, 5H); 13C NMR (213.8 MHz, CD3OD): δ = 171.6, 170.2, 158.63, 158.59, 140.6, 135.1, 133.6, 
129.0, 128.6, 128.5, 128.3, 127.4, 127.2, 126.5, 57.4, 56.4, 48.2, 47.8, 42.4, 41.6, 41.1, 41.0, 38.2, 34.5, 31.2, 
29.7, 29.6, 27.5, 27.3, 26.5: HRMS (ESI): m/z [M + H]+ calcd for C30H45N8O2S+: 581.3381; found 581.3389. 
Purity = 90.9% (UV 220 nm). 
 
4.2. Biology – The final compounds were tested for antagonistic activity against the human CXCR4 in a 
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